Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients

Roland V. Cellona, Maria V.F. Balagon, Eduardo C. Dela Cruz, Jasmin A. Burgos, Rodolfo M. Abalos, Gerald P. Walsh, Richard L Topolski, Robert H. Gelber, Douglas S. Walsh

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Relapse rate estimates after 2 year WHO multiple drug therapy (MDT) in multi-bacillary (MB) leprosy vary. Between 1987 and 1994, 500 MB leprosy patients completing 2 year MDT were enrolled in a prospective relapse study. The majority of patients (N = 316) were treated and followed at the physician-staffed Cebu Skin Clinic (CSC), whereas others (N = 184) received therapy from government clinics and were followed by CSC technicians in the field. Relapse definition was an increased bacteriologic index (BI) and new skin lesions, supplemented with mouse footpad inoculations. Through 2002, follow-up was 5368 person-years, with a mean of 10.8 years per patient. The absolute relapse rate was 3% (15/498; 0.28/100 person-years), with a cumulative risk estimate of 3.9% at 15 yrs. For a subset of 217 patients followed for ≥12 yrs or until relapse, relapses occurred in 9% (13/142) attending the CSC, versus 3% (2/75) assessed in the field (p = 0.09). The rate for patients followed at CSC for ≥12 yrs and a pre-treatment BI ≥2.7+ was 13% (13/98). All relapses were BL or LL, with pre-treatment BI's of ≥2.7+. Relapses occurred long after completion of therapy, between 3 and 11 yrs from the midpoint of the examination without relapse to detection, or between 6 to 13 yrs to the actual year of detection, 7 occurring at ≥10 yrs. Lesion material from all relapses contained M. leprae that was rifampin and clofazimine sensitive, whereas 3 showed partial or full dapsone resistance. [Follow-up rigor and time], medical expertise, and pre-treatment bacterial load influence relapse rates after 2 yr MDT.

Original languageEnglish (US)
Pages (from-to)308-319
Number of pages12
JournalInternational Journal of Leprosy and Other Mycobacterial Diseases
Volume71
Issue number4
DOIs
StatePublished - Dec 1 2003

Fingerprint

Multibacillary Leprosy
Recurrence
Drug Therapy
Skin
Clofazimine
Therapeutics
Dapsone
Bacterial Load
Leprosy
Rifampin

ASJC Scopus subject areas

  • Dermatology

Cite this

Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients. / Cellona, Roland V.; Balagon, Maria V.F.; Dela Cruz, Eduardo C.; Burgos, Jasmin A.; Abalos, Rodolfo M.; Walsh, Gerald P.; Topolski, Richard L; Gelber, Robert H.; Walsh, Douglas S.

In: International Journal of Leprosy and Other Mycobacterial Diseases, Vol. 71, No. 4, 01.12.2003, p. 308-319.

Research output: Contribution to journalArticle

Cellona, Roland V. ; Balagon, Maria V.F. ; Dela Cruz, Eduardo C. ; Burgos, Jasmin A. ; Abalos, Rodolfo M. ; Walsh, Gerald P. ; Topolski, Richard L ; Gelber, Robert H. ; Walsh, Douglas S. / Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients. In: International Journal of Leprosy and Other Mycobacterial Diseases. 2003 ; Vol. 71, No. 4. pp. 308-319.
@article{4453c6850c8c4b38bace44045e3295a9,
title = "Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients",
abstract = "Relapse rate estimates after 2 year WHO multiple drug therapy (MDT) in multi-bacillary (MB) leprosy vary. Between 1987 and 1994, 500 MB leprosy patients completing 2 year MDT were enrolled in a prospective relapse study. The majority of patients (N = 316) were treated and followed at the physician-staffed Cebu Skin Clinic (CSC), whereas others (N = 184) received therapy from government clinics and were followed by CSC technicians in the field. Relapse definition was an increased bacteriologic index (BI) and new skin lesions, supplemented with mouse footpad inoculations. Through 2002, follow-up was 5368 person-years, with a mean of 10.8 years per patient. The absolute relapse rate was 3{\%} (15/498; 0.28/100 person-years), with a cumulative risk estimate of 3.9{\%} at 15 yrs. For a subset of 217 patients followed for ≥12 yrs or until relapse, relapses occurred in 9{\%} (13/142) attending the CSC, versus 3{\%} (2/75) assessed in the field (p = 0.09). The rate for patients followed at CSC for ≥12 yrs and a pre-treatment BI ≥2.7+ was 13{\%} (13/98). All relapses were BL or LL, with pre-treatment BI's of ≥2.7+. Relapses occurred long after completion of therapy, between 3 and 11 yrs from the midpoint of the examination without relapse to detection, or between 6 to 13 yrs to the actual year of detection, 7 occurring at ≥10 yrs. Lesion material from all relapses contained M. leprae that was rifampin and clofazimine sensitive, whereas 3 showed partial or full dapsone resistance. [Follow-up rigor and time], medical expertise, and pre-treatment bacterial load influence relapse rates after 2 yr MDT.",
author = "Cellona, {Roland V.} and Balagon, {Maria V.F.} and {Dela Cruz}, {Eduardo C.} and Burgos, {Jasmin A.} and Abalos, {Rodolfo M.} and Walsh, {Gerald P.} and Topolski, {Richard L} and Gelber, {Robert H.} and Walsh, {Douglas S.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2",
language = "English (US)",
volume = "71",
pages = "308--319",
journal = "International Journal of Leprosy and Other Mycobacterial Diseases",
issn = "0148-916X",
publisher = "Allen Press Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients

AU - Cellona, Roland V.

AU - Balagon, Maria V.F.

AU - Dela Cruz, Eduardo C.

AU - Burgos, Jasmin A.

AU - Abalos, Rodolfo M.

AU - Walsh, Gerald P.

AU - Topolski, Richard L

AU - Gelber, Robert H.

AU - Walsh, Douglas S.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Relapse rate estimates after 2 year WHO multiple drug therapy (MDT) in multi-bacillary (MB) leprosy vary. Between 1987 and 1994, 500 MB leprosy patients completing 2 year MDT were enrolled in a prospective relapse study. The majority of patients (N = 316) were treated and followed at the physician-staffed Cebu Skin Clinic (CSC), whereas others (N = 184) received therapy from government clinics and were followed by CSC technicians in the field. Relapse definition was an increased bacteriologic index (BI) and new skin lesions, supplemented with mouse footpad inoculations. Through 2002, follow-up was 5368 person-years, with a mean of 10.8 years per patient. The absolute relapse rate was 3% (15/498; 0.28/100 person-years), with a cumulative risk estimate of 3.9% at 15 yrs. For a subset of 217 patients followed for ≥12 yrs or until relapse, relapses occurred in 9% (13/142) attending the CSC, versus 3% (2/75) assessed in the field (p = 0.09). The rate for patients followed at CSC for ≥12 yrs and a pre-treatment BI ≥2.7+ was 13% (13/98). All relapses were BL or LL, with pre-treatment BI's of ≥2.7+. Relapses occurred long after completion of therapy, between 3 and 11 yrs from the midpoint of the examination without relapse to detection, or between 6 to 13 yrs to the actual year of detection, 7 occurring at ≥10 yrs. Lesion material from all relapses contained M. leprae that was rifampin and clofazimine sensitive, whereas 3 showed partial or full dapsone resistance. [Follow-up rigor and time], medical expertise, and pre-treatment bacterial load influence relapse rates after 2 yr MDT.

AB - Relapse rate estimates after 2 year WHO multiple drug therapy (MDT) in multi-bacillary (MB) leprosy vary. Between 1987 and 1994, 500 MB leprosy patients completing 2 year MDT were enrolled in a prospective relapse study. The majority of patients (N = 316) were treated and followed at the physician-staffed Cebu Skin Clinic (CSC), whereas others (N = 184) received therapy from government clinics and were followed by CSC technicians in the field. Relapse definition was an increased bacteriologic index (BI) and new skin lesions, supplemented with mouse footpad inoculations. Through 2002, follow-up was 5368 person-years, with a mean of 10.8 years per patient. The absolute relapse rate was 3% (15/498; 0.28/100 person-years), with a cumulative risk estimate of 3.9% at 15 yrs. For a subset of 217 patients followed for ≥12 yrs or until relapse, relapses occurred in 9% (13/142) attending the CSC, versus 3% (2/75) assessed in the field (p = 0.09). The rate for patients followed at CSC for ≥12 yrs and a pre-treatment BI ≥2.7+ was 13% (13/98). All relapses were BL or LL, with pre-treatment BI's of ≥2.7+. Relapses occurred long after completion of therapy, between 3 and 11 yrs from the midpoint of the examination without relapse to detection, or between 6 to 13 yrs to the actual year of detection, 7 occurring at ≥10 yrs. Lesion material from all relapses contained M. leprae that was rifampin and clofazimine sensitive, whereas 3 showed partial or full dapsone resistance. [Follow-up rigor and time], medical expertise, and pre-treatment bacterial load influence relapse rates after 2 yr MDT.

UR - http://www.scopus.com/inward/record.url?scp=1242293831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242293831&partnerID=8YFLogxK

U2 - 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2

DO - 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2

M3 - Article

C2 - 14763888

AN - SCOPUS:1242293831

VL - 71

SP - 308

EP - 319

JO - International Journal of Leprosy and Other Mycobacterial Diseases

JF - International Journal of Leprosy and Other Mycobacterial Diseases

SN - 0148-916X

IS - 4

ER -